LOGIN
CART
MY ACCOUNT
Redeem Quote
North America
Albania
Argentina
Australia
Austria
Belarus
Belgium
Bosnia
Brazil
Bulgaria
Canada
Chile
China
Colombia
Costa Rica
Croatia
Cyprus
Czech Republic
Denmark
Dominican Republic
Ecuador
Egypt
Estonia
Finland
France
French Polynesia
Germany
Greece
Guatemala
Hong Kong
Hungary
Iceland
India
Indonesia
Ireland
Israel
Italy
Japan
Jordan
Kenya
Korea
Kuwait
Latvia
Lebanon
Lithuania
Luxembourg
Macau
Macedonia
Malaysia
Malta
Mexico
Moldova
Morocco
Netherlands
New Zealand
Norway
Oman
Pakistan
Panama
Peru
Philippines
Poland
Portugal
Puerto Rico
Qatar
Romania
Russian Federation
Saudi Arabia
Singapore
Slovakia
Slovenia
South Africa
Spain
Sweden
Switzerland
Taiwan
Thailand
Turkey
Ukraine
United Arab Emirates
United Kingdom
United States
Uruguay
Venezuela
Vietnam
Yemen
Yugoslavia
Zimbabwe
Gene Search
Antigen Profiler
BLAST
Product Search
Enter search terms and hit enter or click the submit button.
Click here
for help with large gene lists
Single letter AA sequence:
Score:
Advanced Peptide Design
Nucleotide
Peptide
(enter accession number or fasta sequence)
Database:
(choose database)
ALL Mammalian
ALL Non-mammalian
Homo sapiens
Mus Musculus
Rat
Canine
Primate
Bos Taurus
Danio rerio
Drosophila (All) (rel.1)
Fugu rubripes (All) (rel.1)
Macaca mulatta (All) (rel.1)
C. jejuni (All) (rel.1)
Xenopus laevis
Xenopus tropicalis
Incyte (All Species)
Submitted
0
Complete
0
Advanced (more options)
Recent Searches
Recent searches
Part of Thermo Fisher Scientific
Products
Promotions
Programs
Distributors
Support
Who We Are
Contact Us
Open Biosystems Responds to Sigma-Aldrich and Oxford Biomedica Lawsuit: Reaffirms Commitment to the Distribution of TRC Lentiviral Libraries
HUNTSVILLE, Ala.—June 15, 2006
Open Biosystems responds to the lawsuit filed by Sigma-Aldrich and Oxford Biomedica alleging patent infringement. Open Biosystems intends to defend these claims and reaffirms its dedication to advancing scientific discoveries through the open distribution of The RNAi Consortium (TRC) lentiviral libraries.
"These large, publicly traded companies have targeted a privately held and socially responsible company with these accusations. The claims of patent infringement in the lawsuit are unfounded, and we intend to vigorously defend against them,” said Troy Moore, chief technology officer, Open Biosystems. “We conduct our business on the highest plane and in a way that results in genomic materials being made available to the research community. It is our belief that there is a greater value in making technologies broadly available both to the holder of the intellectual property and to the research community."
Open Biosystems continues to operate under license from the Broad Institute of MIT and Harvard, the developers of the TRC lentiviral libraries. Sigma-Aldrich also distributes these libraries.
"It is never our policy to infringe upon intellectual property. Open Biosystems’ was founded upon an open source business model that supports basic and medical research by making the newest and best life sciences tools readily available to scientists in academia, government and industry. This business model is disrupting the strategy of large corporate gate-keepers that are determined to control, not advance, research efforts," said Brian Pollock, CEO of Open Biosystems.
About Open Biosystems
Open Biosystems, Inc. develops, manufactures and markets genomic research tools to scientists and researchers in corporate, academic and government laboratories. These research tools provide investigators with standardized high-quality genes, RNAi and antibodies for interrogating gene function in relation to oncology, neuroscience and metabolic disorders. Founded in 2001, Open Biosystems is headquartered in Huntsville, Alabama. For more information and details for ordering, please visit
http://www.openbiosystems.com
.
Open Biosystems, Inc.
888.412-2225
www.openbiosystems.com
info@openbiosystems.com